ADCYAP1 and Miyoshi myopathy: In addition, a recent study identified Pituitary adenylate cyclase-activating polypeptide as a novel noninvasive biomarker of MM,[24] and higher concentration of Pituitary adenylate cyclase-activating polypeptide levels revealed longer survival and better response to the clinical treatment.